Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501851
Benitez Cristian Alejandro , Gomez Ramiro Adrián , Peón Claudia , Alfaro María Agustina , Federico Andrea , Klimovsky Ezequiel , Gamba María Julieta
<div><h3>Objective</h3><div>To correlate ΔRDW and ΔVCM (baseline and week 12) with the number of patients achieving remission or low disease activity by CDAI at week 24 after initiating MTX.</div></div><div><h3>Materials and methods</h3><div>Retro-prospective, analytical, and observational study in consecutive adult patients diagnosed with RA (ACR/EULAR 2010). Demographic data, clinical characteristics, personal history, initiated treatments, and VCM (fL) and RDW (%) at weeks 0, 4, 12, and 24 were evaluated. Safety data was recorded. Statistical analysis: descriptive analysis, Chi<sup>2</sup> test or Fisher's exact test; Student's <em>T</em>-test or Mann–Whitney; and ANOVA or Kruskal–Wallis. Lineal and/or multiple logistic regression.</div></div><div><h3>Results</h3><div>139 patients were included, of whom 109 completed the study requirements. 83.5% were women, median age (m) 50 years (IQR 39–60), with a median disease duration of 12 months (IQR 0–78). In the per-protocol analysis of 109 patients, the m ΔRDW between baseline and week 12 was 0.8 (IQR 0–2.4), and the m ΔVCM was 2.0 (IQR 0.1–4.4). No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.08; <em>p</em> <!-->=<!--> <!-->0.416), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.190; <em>p</em> <!-->=<!--> <!-->0.048).</div><div>Results were analyzed by intention to treat for 139 patients. Between baseline and week 12, a m ΔRDW of 0.8 (IQR 0–2.4) and a m ΔVCM of 2.2 (IQR 0.2–4.5) were recorded. No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.073; <em>p</em> <!-->=<!--> <!-->0.433), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.217; <em>p</em> <!-->=<!--> <!-->0.018). 64.2%, 39.4%, and 15.6% of patients achieved CDAI 50/70/85 responses at week 12, respectively, with no significant changes at week 24. Univariate and multivariate analysis identified that the only factor significantly associated with achieving CDAI 50 at week 24 was achieving such a response at week 12 (<em>p</em> <!-->=<!--> <!-->0.001).</div><div>Safety evaluation showed that 68 patients (48.9%) experienced adverse events, with 20 events (14.4%) related to MTX. Only 5 (3.6%) were considered serious adverse events, all of them unrelated to treatment.</div></div><div><h3>Conclusions</h3><div>This study revealed that an increase in red cell distribution width (RDW) and mean corpuscular volume (VCM) was associated with the initiation of MTX treatment. However, only a significant correlation was found between the change in VCM and RA activity measured by CDAI at week 24. Although ΔRDW did not show a significant association with RA activity, ΔVCM negatively correlated with CDAI at week 24. Additionally, a significant percentage of patients achieved a positive response at week 12, but there were no significant changes at we
{"title":"Mean corpuscular volume and red cell distribution width as predictors of methotrexate response in RA patients","authors":"Benitez Cristian Alejandro , Gomez Ramiro Adrián , Peón Claudia , Alfaro María Agustina , Federico Andrea , Klimovsky Ezequiel , Gamba María Julieta","doi":"10.1016/j.reumae.2025.501851","DOIUrl":"10.1016/j.reumae.2025.501851","url":null,"abstract":"<div><h3>Objective</h3><div>To correlate ΔRDW and ΔVCM (baseline and week 12) with the number of patients achieving remission or low disease activity by CDAI at week 24 after initiating MTX.</div></div><div><h3>Materials and methods</h3><div>Retro-prospective, analytical, and observational study in consecutive adult patients diagnosed with RA (ACR/EULAR 2010). Demographic data, clinical characteristics, personal history, initiated treatments, and VCM (fL) and RDW (%) at weeks 0, 4, 12, and 24 were evaluated. Safety data was recorded. Statistical analysis: descriptive analysis, Chi<sup>2</sup> test or Fisher's exact test; Student's <em>T</em>-test or Mann–Whitney; and ANOVA or Kruskal–Wallis. Lineal and/or multiple logistic regression.</div></div><div><h3>Results</h3><div>139 patients were included, of whom 109 completed the study requirements. 83.5% were women, median age (m) 50 years (IQR 39–60), with a median disease duration of 12 months (IQR 0–78). In the per-protocol analysis of 109 patients, the m ΔRDW between baseline and week 12 was 0.8 (IQR 0–2.4), and the m ΔVCM was 2.0 (IQR 0.1–4.4). No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.08; <em>p</em> <!-->=<!--> <!-->0.416), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.190; <em>p</em> <!-->=<!--> <!-->0.048).</div><div>Results were analyzed by intention to treat for 139 patients. Between baseline and week 12, a m ΔRDW of 0.8 (IQR 0–2.4) and a m ΔVCM of 2.2 (IQR 0.2–4.5) were recorded. No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.073; <em>p</em> <!-->=<!--> <!-->0.433), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.217; <em>p</em> <!-->=<!--> <!-->0.018). 64.2%, 39.4%, and 15.6% of patients achieved CDAI 50/70/85 responses at week 12, respectively, with no significant changes at week 24. Univariate and multivariate analysis identified that the only factor significantly associated with achieving CDAI 50 at week 24 was achieving such a response at week 12 (<em>p</em> <!-->=<!--> <!-->0.001).</div><div>Safety evaluation showed that 68 patients (48.9%) experienced adverse events, with 20 events (14.4%) related to MTX. Only 5 (3.6%) were considered serious adverse events, all of them unrelated to treatment.</div></div><div><h3>Conclusions</h3><div>This study revealed that an increase in red cell distribution width (RDW) and mean corpuscular volume (VCM) was associated with the initiation of MTX treatment. However, only a significant correlation was found between the change in VCM and RA activity measured by CDAI at week 24. Although ΔRDW did not show a significant association with RA activity, ΔVCM negatively correlated with CDAI at week 24. Additionally, a significant percentage of patients achieved a positive response at week 12, but there were no significant changes at we","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501851"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501857
Leonardo F. Freitas , Márcio Luís Duarte , Kevin J. Abrams
{"title":"Novel imaging findings of masticatory muscle edema in dermatomyositis associated with ovarian cancer: A case report","authors":"Leonardo F. Freitas , Márcio Luís Duarte , Kevin J. Abrams","doi":"10.1016/j.reumae.2025.501857","DOIUrl":"10.1016/j.reumae.2025.501857","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501857"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144239764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarcoidosis is a multisystemic granulomatous disease of uncertain etiology. Several drugs have been linked to the development of sarcoidosis or systemic granulomatous reactions indistinguishable from this disease. We present the clinical case of a patient diagnosed with breast cancer and undergoing treatment with capecitabine who, after developing systemic and musculoskeletal symptoms, was ultimately diagnosed with capecitabine-induced sarcoidosis.
{"title":"Capecitabine-induced sarcoidosis in an oncology patient: Clinical presentation with arthritis","authors":"Yedra Usón-Rodríguez , Fátima Mocha-Campillo , Maialen Guerrero-Gómez , Juan Lao-Romera , Marina Soledad Moreno-García","doi":"10.1016/j.reumae.2025.501870","DOIUrl":"10.1016/j.reumae.2025.501870","url":null,"abstract":"<div><div>Sarcoidosis is a multisystemic granulomatous disease of uncertain etiology. Several drugs have been linked to the development of sarcoidosis or systemic granulomatous reactions indistinguishable from this disease. We present the clinical case of a patient diagnosed with breast cancer and undergoing treatment with capecitabine who, after developing systemic and musculoskeletal symptoms, was ultimately diagnosed with capecitabine-induced sarcoidosis.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501870"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501845
Carlota Navarro-Joven , María Alonso de Francisco , Margarita Pich-Aguilera Blasco , Rita María Cabeza Martínez , José Luis Andreu Sánchez , Hildegarda Godoy-Tundidor
Rowell’s syndrome (RS) is an unusual form of subacute cutaneous lupus. We present the case of a male patient with chronic RS who exhibits a remarkable response to anifrolumab.
{"title":"Use of anifrolumab in a patient with chronic multirefractory Rowell’s syndrome","authors":"Carlota Navarro-Joven , María Alonso de Francisco , Margarita Pich-Aguilera Blasco , Rita María Cabeza Martínez , José Luis Andreu Sánchez , Hildegarda Godoy-Tundidor","doi":"10.1016/j.reumae.2025.501845","DOIUrl":"10.1016/j.reumae.2025.501845","url":null,"abstract":"<div><div>Rowell’s syndrome (RS) is an unusual form of subacute cutaneous lupus. We present the case of a male patient with chronic RS who exhibits a remarkable response to anifrolumab.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501845"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501856
Osmar Antonio Centurión , Paloma de Abreu , Gabriela Avila-Pedretti , Sonia R. Cabrera , María T. Martínez de Filártiga , Astrid Paats , Judith M. Torales , Christian O. Chávez , Carmen R. Montiel , Laura B. García , Karina E. Scavenius , Rocío del Pilar Falcón , Jose C. Candia , Alfredo J. Meza , Isabel Acosta-Colmán
Objectives
Serum vascular endothelial growth factor (VEGF) levels correlate with structural alterations in Rheumatoid Arthritis (RA). Since P wave dispersion (PWD) is associated with atrial ischemic-related fibrotic changes, it was conceived that there may be a correlation between altered PWD and increased VEGF levels in RA.
Methods
In this prospective observational study, we evaluated patients with RA, and compared them to control subjects. PWD was considered as the difference between the maximum and minimum duration of the P wave. An altered PWD was considered one that had dispersion ≥ 38 ms. Measurements of VEGF serum levels were performed using enzyme-ligand, immunosorbent measurement ELISA kits.
Results
A total of 99 patients with RA, and 48 control subjects were evaluated. The PWD was 25.3 ± 4.9 ms in the control group vs. 57 ± 14.9 ms (p < 0.0001) in the RA group. No patient in the control group had altered PWD, while 94 (95%) patients in the RA group presented it (p < 0.0001). The value of VEGF in the control group was 15.2 ± 15.1 pg/ml vs 51.1 ± 55.5 pg/ml (p < 0.001) in RA. The value of VEGF in RA without altered PWD was 20 ± 12 pg/ml vs 56 ± 57 pg/ml in RA with altered PWD (p < 0.02). An elevated VEGF value had a specificity of 80%, and a positive predictive accuracy of 95% in predicting altered PWD in RA.
Conclusions
This study establishes for the first time that RA patients who possess significantly higher serum levels of VEGF have an altered PWD. The presence of an elevated VEGF serum value has a high specificity, and high positive predictive accuracy of the existence of altered PWD in RA.
目的：血清血管内皮生长因子（VEGF）水平与类风湿关节炎（RA）的结构改变相关。由于P波弥散度（PWD）与心房缺血相关的纤维化改变有关，因此我们认为RA中PWD改变与VEGF水平升高可能存在相关性。方法在这项前瞻性观察性研究中，我们对RA患者进行评估，并将其与对照组进行比较。PWD被认为是P波最大持续时间与最小持续时间之差。改变的PWD被认为弥散≥38 ms。采用酶配体、免疫吸附测定ELISA试剂盒测定血清VEGF水平。结果共对99例RA患者和48例对照组进行评估。对照组PWD为25.3±4.9 ms，对照组为57±14.9 ms (p <；0.0001)。对照组无PWD改变，而RA组有94例（95%）患者出现PWD改变(p <；0.0001)。对照组VEGF值分别为15.2±15.1 pg/ml vs 51.1±55.5 pg/ml (p <；0.001)。未改变PWD的RA组VEGF值为20±12 pg/ml，而改变PWD的RA组VEGF值为56±57 pg/ml (p <；0.02)。VEGF升高在预测RA患者PWD改变方面的特异性为80%，阳性预测准确率为95%。结论本研究首次证实血清VEGF水平显著升高的RA患者PWD发生改变。VEGF血清值升高对RA中PWD改变的存在具有高特异性和高阳性预测准确性。
{"title":"Association of electrocardiographic altered P wave dispersion and vascular endothelial growth factor in rheumatoid arthritis","authors":"Osmar Antonio Centurión , Paloma de Abreu , Gabriela Avila-Pedretti , Sonia R. Cabrera , María T. Martínez de Filártiga , Astrid Paats , Judith M. Torales , Christian O. Chávez , Carmen R. Montiel , Laura B. García , Karina E. Scavenius , Rocío del Pilar Falcón , Jose C. Candia , Alfredo J. Meza , Isabel Acosta-Colmán","doi":"10.1016/j.reumae.2025.501856","DOIUrl":"10.1016/j.reumae.2025.501856","url":null,"abstract":"<div><h3>Objectives</h3><div>Serum vascular endothelial growth factor (VEGF) levels correlate with structural alterations in Rheumatoid Arthritis (RA). Since P wave dispersion (PWD) is associated with atrial ischemic-related fibrotic changes, it was conceived that there may be a correlation between altered PWD and increased VEGF levels in RA.</div></div><div><h3>Methods</h3><div>In this prospective observational study, we evaluated patients with RA, and compared them to control subjects. PWD was considered as the difference between the maximum and minimum duration of the P wave. An altered PWD was considered one that had dispersion<!--> <!-->≥<!--> <!-->38<!--> <!-->ms. Measurements of VEGF serum levels were performed using enzyme-ligand, immunosorbent measurement ELISA kits.</div></div><div><h3>Results</h3><div>A total of 99 patients with RA, and 48 control subjects were evaluated. The PWD was 25.3<!--> <!-->±<!--> <!-->4.9<!--> <!-->ms in the control group vs. 57<!--> <!-->±<!--> <!-->14.9<!--> <!-->ms (<em>p</em> <!--><<!--> <!-->0.0001) in the RA group. No patient in the control group had altered PWD, while 94 (95%) patients in the RA group presented it (<em>p</em> <!--><<!--> <!-->0.0001). The value of VEGF in the control group was 15.2<!--> <!-->±<!--> <!-->15.1<!--> <!-->pg/ml vs 51.1<!--> <!-->±<!--> <!-->55.5<!--> <!-->pg/ml (<em>p</em> <!--><<!--> <!-->0.001) in RA. The value of VEGF in RA without altered PWD was 20<!--> <!-->±<!--> <!-->12<!--> <!-->pg/ml vs 56<!--> <!-->±<!--> <!-->57<!--> <!-->pg/ml in RA with altered PWD (<em>p</em> <!--><<!--> <!-->0.02). An elevated VEGF value had a specificity of 80%, and a positive predictive accuracy of 95% in predicting altered PWD in RA.</div></div><div><h3>Conclusions</h3><div>This study establishes for the first time that RA patients who possess significantly higher serum levels of VEGF have an altered PWD. The presence of an elevated VEGF serum value has a high specificity, and high positive predictive accuracy of the existence of altered PWD in RA.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501856"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144239259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501848
Carlos Antonio Guillén-Astete , Boris Blanco Cáceres , Jaime Arroyo Palomo , Aliuska Malena Palomeque Vargas , Marta Serrano Warleta , Ana María Ruiz Bejerano , Ana Sánchez-Poves García , Javier Bachiller Corral , Mónica Vázquez-Díaz
Introduction
Ultrasound-guided synovial biopsy is a procedure for diagnostic and research purposes that is not yet available in most rheumatology departments.
Methods
We describe the experience with synovial biopsy procedures in our department.
Results
Thirty-eight synovial biopsies were performed on 33 patients during observation. The patients' mean age (standard deviation) was 59 (17) years, ranging between 26 and 90 years. The most frequently biopsied territories were the carpus and the knee. No complications occurred during the procedures. Sixteen residents were trained in the procedure. Two joint sessions have been held with the Immunology and Anatomical Pathology services, and our service sessions have been organised based on the scope and usefulness of the procedures.
Conclusions
Our service's experience has been positive regarding patient care and resident training. The procedure has had no serious complications and has been, in general, very well tolerated.
{"title":"Experience after implementation of ultrasound-guided synovial biopsy in a Rheumatology Department","authors":"Carlos Antonio Guillén-Astete , Boris Blanco Cáceres , Jaime Arroyo Palomo , Aliuska Malena Palomeque Vargas , Marta Serrano Warleta , Ana María Ruiz Bejerano , Ana Sánchez-Poves García , Javier Bachiller Corral , Mónica Vázquez-Díaz","doi":"10.1016/j.reumae.2025.501848","DOIUrl":"10.1016/j.reumae.2025.501848","url":null,"abstract":"<div><h3>Introduction</h3><div>Ultrasound-guided synovial biopsy is a procedure for diagnostic and research purposes that is not yet available in most rheumatology departments.</div></div><div><h3>Methods</h3><div>We describe the experience with synovial biopsy procedures in our department.</div></div><div><h3>Results</h3><div>Thirty-eight synovial biopsies were performed on 33 patients during observation. The patients' mean age (standard deviation) was 59 (17) years, ranging between 26 and 90 years. The most frequently biopsied territories were the carpus and the knee. No complications occurred during the procedures. Sixteen residents were trained in the procedure. Two joint sessions have been held with the Immunology and Anatomical Pathology services, and our service sessions have been organised based on the scope and usefulness of the procedures.</div></div><div><h3>Conclusions</h3><div>Our service's experience has been positive regarding patient care and resident training. The procedure has had no serious complications and has been, in general, very well tolerated.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501848"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501849
Melek Aykut Selçuk , Gülseren Demir Karakılıç , Esra Mert , Burcu Duyur Çakıt
Introduction
We aimed to evaluate pain, kinesiophobia, physical activity, depression, disease severity and fatigue in patients with Fibromyalgia syndrome (FMS) and chronic neck pain (CNP) and healthy controls.
Material and methods
Fifty-two patients with FMS (group 1), 52 patients with CNP (group 2) and 52 healthy controls (group 3) were included in the study. Visual Analog Scale (VAS) was used to evaluate pain intensity and fatigue, Tampa Scale of Kinesiophobia (TSK) for kinesiophobia, Beck Depression Inventory (BDI) for depression, International Physical Activity Questionnaire (IPAQ) Short Form for physical activity level, Revised Fibromyalgia Impact Questionnaire (rFIQ) for functional status in FMS, and Neck Pain Disability Index (NPDI) for neck pain-related disability in patients with CNP.
Results
The mean age was similar in all three groups (42.96) and the ratio of female was higher in all three groups (94.2%, 90%, 88.6%). High level kinesiophobia was present in 86.6% of patients in group 1, 63.3% of patients in group 2 and 23.4% of participants in group 3 and statistically, kinesiophobia was more common in groups 1 than in groups 2 and 3 and in group 2 than in group 3. The rate of depression was 80%, 50% and 16% in groups 1, 2 and 3, respectively. In group 1, 70% of patients had low, 23.3% had moderate, and 6.6% had high physical activity levels. In group 2, 46.6% of patients had low, 36.6% had moderate, and 16.6% had high physical activity levels; in group 3, 23.3% had low, 53.4% had moderate, and 23.3% had high physical activity levels. There was a statistically significant difference in physical activity levels among the three groups and between group 1 and group 3 (p < 0.05), but no statistically significant difference was revealed in the remaining paired comparisons (p > 0.05). TSK score was positively and weakly correlated with VAS-pain (p:0.032, r:0.392) and rFIQ scores (p:0.025, r:0.408) in group 1, positively and strongly correlated with BDI scores (p:0.002, r:0.547) in group 1, and negatively and weakly correlated with physical activity levels (p:0.039, r: −0.378) in group 2.
Conclusions
The patients with group 1 and group 2 had higher levels of kinesiophobia, pain intensity, fatigue and a lower physical activity level than group 3.
{"title":"Evaluation of kinesiophobia and physical activity levels in patients with fibromyalgia syndrome and chronic neck pain","authors":"Melek Aykut Selçuk , Gülseren Demir Karakılıç , Esra Mert , Burcu Duyur Çakıt","doi":"10.1016/j.reumae.2025.501849","DOIUrl":"10.1016/j.reumae.2025.501849","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate pain, kinesiophobia, physical activity, depression, disease severity and fatigue in patients with Fibromyalgia syndrome (FMS) and chronic neck pain (CNP) and healthy controls.</div></div><div><h3>Material and methods</h3><div>Fifty-two patients with FMS (group 1), 52 patients with CNP (group 2) and 52 healthy controls (group 3) were included in the study. Visual Analog Scale (VAS) was used to evaluate pain intensity and fatigue, Tampa Scale of Kinesiophobia (TSK) for kinesiophobia, Beck Depression Inventory (BDI) for depression, International Physical Activity Questionnaire (IPAQ) Short Form for physical activity level, Revised Fibromyalgia Impact Questionnaire (rFIQ) for functional status in FMS, and Neck Pain Disability Index (NPDI) for neck pain-related disability in patients with CNP.</div></div><div><h3>Results</h3><div>The mean age was similar in all three groups (42.96) and the ratio of female was higher in all three groups (94.2%, 90%, 88.6%). High level kinesiophobia was present in 86.6% of patients in group 1, 63.3% of patients in group 2 and 23.4% of participants in group 3 and statistically, kinesiophobia was more common in groups 1 than in groups 2 and 3 and in group 2 than in group 3. The rate of depression was 80%, 50% and 16% in groups 1, 2 and 3, respectively. In group 1, 70% of patients had low, 23.3% had moderate, and 6.6% had high physical activity levels. In group 2, 46.6% of patients had low, 36.6% had moderate, and 16.6% had high physical activity levels; in group 3, 23.3% had low, 53.4% had moderate, and 23.3% had high physical activity levels. There was a statistically significant difference in physical activity levels among the three groups and between group 1 and group 3 (<em>p</em> <!--><<!--> <!-->0.05), but no statistically significant difference was revealed in the remaining paired comparisons (<em>p</em> <!-->><!--> <!-->0.05). TSK score was positively and weakly correlated with VAS-pain (<em>p</em>:0.032, <em>r</em>:0.392) and rFIQ scores (<em>p</em>:0.025, <em>r</em>:0.408) in group 1, positively and strongly correlated with BDI scores (<em>p</em>:0.002, <em>r</em>:0.547) in group 1, and negatively and weakly correlated with physical activity levels (<em>p</em>:0.039, <em>r</em>: −0.378) in group 2.</div></div><div><h3>Conclusions</h3><div>The patients with group 1 and group 2 had higher levels of kinesiophobia, pain intensity, fatigue and a lower physical activity level than group 3.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501849"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144239326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501871
Sarah Aijaz , Raveen Muzaffer
{"title":"Comment on: “Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: Data from the BIOBADAGUAY registry”","authors":"Sarah Aijaz , Raveen Muzaffer","doi":"10.1016/j.reumae.2025.501871","DOIUrl":"10.1016/j.reumae.2025.501871","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501871"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sjögren's disease it's a heterogeneous and complex rheumatological disease, can present central neurological manifestations, with a prevalence that varies between 1–5% according to the international literature. We report a series of three cases; we present a patient who debuted with epileptic seizures, one with catatonic syndrome and a last one with optic neuritis. Knowing the various presentations of the central neurological manifestations allows us to broaden the diagnostic suspicion from the beginning, providing timely treatment.
{"title":"Central neurological symptoms as the first manifestation in Sjögren’s disease","authors":"Dianela Gasca Saldaña , Wallace Rafael Arturo Muñoz Castañeda , Antonio Gonzalez Pineda , Karen Burgueño Aguilar , Andrés Vega Rosas","doi":"10.1016/j.reumae.2025.501846","DOIUrl":"10.1016/j.reumae.2025.501846","url":null,"abstract":"<div><div>Sjögren's disease it's a heterogeneous and complex rheumatological disease, can present central neurological manifestations, with a prevalence that varies between 1–5% according to the international literature. We report a series of three cases; we present a patient who debuted with epileptic seizures, one with catatonic syndrome and a last one with optic neuritis. Knowing the various presentations of the central neurological manifestations allows us to broaden the diagnostic suspicion from the beginning, providing timely treatment.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501846"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.reumae.2025.501816
Paula Pérez Jiménez , Laura Tío Barrera , José Luis Andréu Sánchez , Tarek Carlos Salman-Monte , Irene Carrión-Barberà
Background
Patients with systemic lupus erythematosus (SLE) and anti-Ro+ antibody frequently pose a diagnostic and therapeutic challenge for the specialist, as they frequently present sicca syndrome, overlapping with Sjögren's syndrome (SS). To date, the clinical and prognostic variability that this antibody confers on SLE patients is not well characterized.
Objectives
To investigate the possible clinical, analytical, therapeutic and prognostic implications of anti-Ro antibody in SLE. Furthermore, we analyzed the possible implications of the expressed anti-Ro profile (subunit 52, 60 or both) on the disease phenotype.
Methods
The medical records of patients with anti-Ro+ and - SLE, primary SS and SLE/SS overlap have been reviewed.
Results
Anti-Ro+ SLE presents less arthritis, low C4, expression of DNA Crithidia and need for bolus corticosteroids than anti-Ro− SLE, but more xerophthalmia, xerostomia, expression of anti-La, anti-cyclic citrullinated peptide and overlap with other rheumatological entities. Anti-Ro+ SLE and the overlap group behave similarly for multiple variables. SS group shows a higher expression of β2-microglobulin compared to the overlap group. Anti-Ro52+ patients associate more Raynaud's phenomenon than anti-Ro60+ patients. The latter express more lupus anticoagulant and antiphospholipid antibodies than the group with both subunits.
Conclusions
The presence of anti-Ro+ in patients with SLE provides clinical and analytical differences compared to patients with anti-Ro− SLE and SLE/SS. anti-Ro+ SLE and the overlap group behave similarly, but present differential characteristics that postulate them as separate phenotypes of the disease. The different serological profiles of anti-Ro confer specific clinical and analytical characteristics in patients with SLE and SS.
{"title":"Role of the anti-RO/SSA antibody in patients with systemic lupus erythematosus","authors":"Paula Pérez Jiménez , Laura Tío Barrera , José Luis Andréu Sánchez , Tarek Carlos Salman-Monte , Irene Carrión-Barberà","doi":"10.1016/j.reumae.2025.501816","DOIUrl":"10.1016/j.reumae.2025.501816","url":null,"abstract":"<div><h3>Background</h3><div>Patients with systemic lupus erythematosus (SLE) and anti-Ro+ antibody frequently pose a diagnostic and therapeutic challenge for the specialist, as they frequently present sicca syndrome, overlapping with Sjögren's syndrome (SS). To date, the clinical and prognostic variability that this antibody confers on SLE patients is not well characterized.</div></div><div><h3>Objectives</h3><div>To investigate the possible clinical, analytical, therapeutic and prognostic implications of anti-Ro antibody in SLE. Furthermore, we analyzed the possible implications of the expressed anti-Ro profile (subunit 52, 60 or both) on the disease phenotype.</div></div><div><h3>Methods</h3><div>The medical records of patients with anti-Ro+ and - SLE, primary SS and SLE/SS overlap have been reviewed.</div></div><div><h3>Results</h3><div>Anti-Ro+ SLE presents less arthritis, low C4, expression of DNA Crithidia and need for bolus corticosteroids than anti-Ro− SLE, but more xerophthalmia, xerostomia, expression of anti-La, anti-cyclic citrullinated peptide and overlap with other rheumatological entities. Anti-Ro+ SLE and the overlap group behave similarly for multiple variables. SS group shows a higher expression of β2-microglobulin compared to the overlap group. Anti-Ro52+ patients associate more Raynaud's phenomenon than anti-Ro60+ patients. The latter express more lupus anticoagulant and antiphospholipid antibodies than the group with both subunits.</div></div><div><h3>Conclusions</h3><div>The presence of anti-Ro+ in patients with SLE provides clinical and analytical differences compared to patients with anti-Ro− SLE and SLE/SS. anti-Ro+ SLE and the overlap group behave similarly, but present differential characteristics that postulate them as separate phenotypes of the disease. The different serological profiles of anti-Ro confer specific clinical and analytical characteristics in patients with SLE and SS.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 3","pages":"Article 501816"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：